Hirtle Callaghan & Co’s Gilead Sciences GILD Stock Holding History

Hirtle Callaghan & Co’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,447	Closed	-$275K	–	113
2022 Q2	$275K	Hold	4,447	–	–	0.02%	108
2022 Q1	$264K	Buy	+4,447	New	+$284K	0.01%	118
2017 Q4	–	Sell	-404	Closed	-$33K	–	182
2017 Q3	$33K	Hold	404	–	–	﹤0.01%	121
2017 Q2	$28K	Sell	404 -100	-20%	-$6.65K	﹤0.01%	104
2017 Q1	$34K	Sell	504 -1,700	-77%	-$120K	0.01%	108
2016 Q4	$158K	Sell	2,204 -1,148	-34%	-$85.3K	0.03%	29
2016 Q3	$265K	Buy	3,352 +850	+34%	+$69K	0.05%	76
2016 Q2	$209K	Sell	2,502 -1,566	-38%	-$139K	0.04%	79
2016 Q1	$374K	Hold	4,068	–	–	0.07%	60
2015 Q4	$411K	Sell	4,068 -73	-2%	-$7.6K	0.1%	17
2015 Q3	$408K	Hold	4,141	–	–	0.07%	29
2015 Q2	$485K	Buy	+4,141	New	+$452K	0.16%	22
2015 Q1	–	Sell	-6,456	Closed	-$609K	–	160
2014 Q4	$609K	Buy	6,456 +2,594	+67%	+$268K	0.14%	94
2014 Q3	$411K	Sell	3,862 -138	-3%	-$13.5K	0.07%	123
2014 Q2	$332K	Buy	4,000 +800	+25%	+$62.3K	0.05%	188
2014 Q1	$227K	Buy	3,200 +2,300	+256%	+$180K	0.04%	224
2013 Q4	$68K	Buy	+900	New	+$62.7K	0.01%	300

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hirtle Callaghan & Co's GILD Position: Q3 2022 in Review

Hirtle Callaghan & Co sold out of Gilead Sciences (GILD) in Q3 2022, closing a stake of 4,447 shares — an estimated $275K sold.

Hirtle Callaghan & Co first reported a position in GILD in Q4 2013 and held it in 17 quarters. The position peaked at $609K in Q4 2014. 1,602 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

Hirtle Callaghan & Co reported no remaining Gilead Sciences position as of Q3 2022 after selling out during the quarter.
Hirtle Callaghan & Co sold 4,447 Gilead Sciences shares in Q3 2022, an estimated $275K.
Hirtle Callaghan & Co first reported a position in Gilead Sciences in Q4 2013 and held it in 17 quarters.
Hirtle Callaghan & Co's Gilead Sciences position peaked at $609K in Q4 2014.
1,602 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on Hirtle Callaghan & Co's 13F filing for Q3 2022, filed 14 Nov 2022.